Possible Legislation Regarding ESA Administration On The Horizon
This article was originally published in The Pink Sheet Daily
Executive Summary
OIG report on administration protocols for erythropoiesis-stimulating agents at dialysis facilities for renal disease patients could lay foundation for possible legislation or CMS administrative action, a staffer for Rep. Stark says.
You may also be interested in...
CMS Defends Oral ESRD Drug Inclusion In Proposed Bundling Rule
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
ESRD Bundling Debate Shifts To Congress With Receipt Of CMS Report
Congress will start looking at the specifics of how to bundle payment for a variety of services related to end-stage renal disease treatment, now that CMS has issued a report on the subject
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.